Back to top
more

Matinas Biopharma (MTNB)

(Delayed Data from AMEX)

$0.18 USD

0.18
767,398

0.00 (-0.71%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $0.18 0.00 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MTNB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Matinas Biopharma Holdings, Inc. [MTNB]

Reports for Purchase

Showing records 1 - 20 ( 71 total )

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 1

03/03/2023

Company Report

Pages: 5

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 2

01/31/2023

Daily Note

Pages: 4

2023 Outlook-MAT2203 Has Paved Path for Nucleic Acids and Broader Collaboration Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 3

11/03/2022

Company Report

Pages: 7

MAT2203 Progress-Phase 3 Initiation in CM Expected 1Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 4

10/24/2022

Daily Note

Pages: 4

MAT2203 Delivers in EnACT Trial-1Q23 Sights Focused on Phase 3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 5

08/12/2022

Company Report

Pages: 7

MAT2203 Paves Way For LNC Platform, Collaboration Upside; Reit Buy and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 6

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 7

05/13/2022

Company Report

Pages: 7

MAT2203 Phase 2 EnACT Top-Line Expected 3Q22-Thoughts on Program Advancement

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 8

04/11/2022

Daily Note

Pages: 5

LNC Drug Delivery Platform Attracts BioNTech Collaboration

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 9

03/09/2022

Company Report

Pages: 7

LNC Platform Advancement With MAT2203 Top-Line Expected 3Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 10

01/26/2022

Daily Note

Pages: 4

MAT2203 Leads LNC Charge-Next EnACT Cohort Topline Anticipated 3Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 11

11/09/2021

Company Report

Pages: 7

MAT2203 Phase 2 EnACT Advancement Leads LNC Validation

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 12

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MTNB

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 13

09/14/2021

Daily Note

Pages: 4

Initial MAT2203 Cohorts Further Validate Merits of LNC Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 14

08/11/2021

Company Report

Pages: 7

LNC Platform Front and Center With EnACT Progress; Near-Term Cohort Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 15

06/18/2021

Daily Note

Pages: 4

Our Thoughts on R&D Day Broad Applicability for LNC Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 16

05/11/2021

Company Report

Pages: 7

LNC Delivery Pipeline Rebranding; Next Sights on MAT2203 Data Expected 3Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 17

03/30/2021

Company Report

Pages: 8

LNC Platform Takes Center Stage in Strategic Shift From Lypdiso; PT to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 18

02/02/2021

Company Report

Pages: 4

Leveraging Focus on EPA Bioavailability Amid ENHANCE-IT Top Line

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 19

11/09/2020

Company Report

Pages: 8

In Shifting OM3 Landscape, MAT9001 Stands Chance for Differentiated Benefit

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 20

08/11/2020

Company Report

Pages: 8

Considerations for the Omega-3 Landscape, and Opportunity to ENHANCE-IT; Reit Buy and $4 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party